NSEGeneral Updates26 Jun 2026 · 26 Jun 2026, 06:26 pm
General Updates
Medplus Health Services Limited · MEDPLUS
✦ AI Summary▼ NegativeRegulatory
MedPlus Health Services Limited has received three suspension orders for a Drug License of its subsidiary Optival Health Solutions Private Limited, resulting in a potential revenue loss of Rs 0.22 lacs, Rs 0.60 lacs, and Rs 0.76 lacs for one, two, and three days respectively.
Analysis Scores
Earnings Impact6/10
Growth Catalyst1/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment4/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Attachments (1)
📄pdf
Download →
MEDPLUS_26062026182606_Intimation.pdf
View document text
MedPlus Health Services Limited
June 26, 2026
The Listing Department The Listing Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor
Dalal Street, Fort, Plot No. C/1, G Block,
Mumbai – 400001 Bandra - Kurla Complex
BSE Scrip Code: 543427 Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS
Dear Sir/Madam,
Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015
We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has received
three suspension orders for a Drug License of a store situated in the state of Karnataka and Andra Pradesh:
Pursuant to SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD
POD2/I/3762/2026 dated January 30, 2026, the details of the matter are as follows:
Name(s) of the Authority Nature and details of the Date of receipt of Details of the Impact on financial
action(s) taken, initiated direction or order, violation(s)/ operation or other
or order(s) passed including any contravention(s) activities of the
interim or interim committed or alleged listed entity,
orders, or any other to be committed quantifiable in
communication monetary terms to
from the authority the extent possible
Assistant Director,Drugs Suspension of Drug Potential Revenue
Control Administration, Hubli License for one day of Loss of Rs 0.22 lacs.
Circle, Hubli Karnataka. store situated at Adarsha
Nagar Hubli , Karnataka.
Assistant Director, Drugs Suspension of Drug Potential Revenue
Order received on Under Rule 65 of Drugs
Control Adminstration, Gadag License for two days of Loss of Rs 0.60 lacs.
25.06.2026 and Cosmetics Act,
Circle, Gadag Karnataka. store situated at Rani
1940 and Drugs and
Road Gadag, Karnataka.
Cosmetics Rules, 1945
Assistant Director, Drugs Suspension of Drug Potential Revenue
Control Administration, License for three days of Loss of Rs 0.76 lacs.
Serilingampally Andra pradesh. store situated
Radhakrishna Nagar
Attapur Andra pradesh
The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE
Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Kindly take
the same on records.
For MedPlus Health Services Limited
Gangadi Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097
040-6724 672
Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India
CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com